Study identifier:NIS-CFR-DUM-2009/2
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Evaluation of target organs damage in hypertensive patients followed in general practice with no known cardiovascular (CV) or renal disease, stratified according to blood pressure control
target organs damage
-
No
-
All
1857
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Dec 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control
Location
Location
ABBARETZ, France
Location
ACHENHEIM, France
Location
ACHERES, France
Location
ACHICOURT, France
Location
AGDE, France
Location
AIGURANDE, France
Location
AIX EN PROVENCE, France
Location
AIX LES BAINS, France
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.